HRP20201412T1 - Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda - Google Patents
Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda Download PDFInfo
- Publication number
- HRP20201412T1 HRP20201412T1 HRP20201412TT HRP20201412T HRP20201412T1 HR P20201412 T1 HRP20201412 T1 HR P20201412T1 HR P20201412T T HRP20201412T T HR P20201412TT HR P20201412 T HRP20201412 T HR P20201412T HR P20201412 T1 HRP20201412 T1 HR P20201412T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- piperazinyl
- sulfonyl
- methoxy
- indole
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims 8
- 229940099433 NMDA receptor antagonist Drugs 0.000 title claims 6
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title claims 6
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 25
- GWCYPEHWIZXYFZ-UHFFFAOYSA-N masupirdine Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 GWCYPEHWIZXYFZ-UHFFFAOYSA-N 0.000 claims 15
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 10
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical group Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 6
- 229960003530 donepezil Drugs 0.000 claims 5
- 239000003751 serotonin 6 antagonist Substances 0.000 claims 5
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- 229960004640 memantine Drugs 0.000 claims 4
- XKDCUJBWVGDNSH-UHFFFAOYSA-N 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole;methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O.CS(O)(=O)=O.C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 XKDCUJBWVGDNSH-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical group [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims 2
- 229960003135 donepezil hydrochloride Drugs 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229960004136 rivastigmine Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- PIQRFUCZSGOHKB-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC(F)=CC=2)C=C1CN1CCN(C)CC1 PIQRFUCZSGOHKB-UHFFFAOYSA-N 0.000 claims 1
- MZPDNMSIIFZBTH-UHFFFAOYSA-N 1-(4-fluorophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole dihydrochloride Chemical compound Cl.Cl.COc1ccc2n(cc(CN3CCN(C)CC3)c2c1)S(=O)(=O)c1ccc(F)cc1 MZPDNMSIIFZBTH-UHFFFAOYSA-N 0.000 claims 1
- KEPYHFKGGRLKPU-UHFFFAOYSA-N 5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1-(4-propan-2-ylphenyl)sulfonylindole Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C(C)C)C=C1CN1CCN(C)CC1 KEPYHFKGGRLKPU-UHFFFAOYSA-N 0.000 claims 1
- MYIZVVVLXBGPQY-UHFFFAOYSA-N 5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1-(4-propan-2-ylphenyl)sulfonylindole dihydrochloride Chemical compound Cl.Cl.COc1ccc2n(cc(CN3CCN(C)CC3)c2c1)S(=O)(=O)c1ccc(cc1)C(C)C MYIZVVVLXBGPQY-UHFFFAOYSA-N 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (19)
1. Kombinacija koja sadrži čisti antagonist receptora 5-HT6, inhibitor acetilkolinesteraze i antagonist receptora NMDA, naznačena time što je čisti antagonist receptora 5-HT6 odabran iz grupe koja se sastoji od:
1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola;
1-[(4-fluorofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola; i
1-[(4-izopropilfenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola;
ili njihove farmaceutski prihvatljive soli.
2. Kombinacija kao što je navedeno u patentnom zahtjevu 1, naznačena time što je inhibitor acetilkolinesteraze odabran iz grupe koja se sastoji od donepezila, rivastigmina i galantamina ili njihove farmaceutski prihvatljive soli.
3. Kombinacija kao što je navedeno u patentnom zahtjevu 1, naznačena time što je antagonist receptora NMDA memantin ili njegova farmaceutski prihvatljiva sol; izborno pri čemu je antagonist receptora NMDA memantin hidroklorid.
4. Kombinacija kao što je navedeno u bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je čisti antagonist receptora 5-HT6 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol.
5. Kombinacija kao što je navedeno u bilo kojem od patentnih zahtjeva 1 do 4, naznačena time što je farmaceutski prihvatljiva sol čistog antagonista receptora 5-HT6 odabrana od:
1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilat monohidrata;
1-[(4-fluorofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dihidroklorida; i
1-[(4-izopropilfenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dihidroklorida.
6. Kombinacija kao što je navedeno u bilo kojem od patentnih zahtjeva 1 do 5, naznačena time što je čisti antagonist receptora 5-HT6 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilat monohidrat.
7. Kombinacija kao što je navedeno u bilo kojem od patentnih zahtjeva 1 ili 2 naznačena time što je inhibitor acetilkolinesteraze donepezil ili njegova farmaceutski prihvatljiva sol; izborno pri čemu je inhibitor acetilkolinesteraze donepezil hidroklorid.
8. Kombinacija koja sadrži 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilat monohidrat, donepezil hidroklorid i memantin hidroklorid.
9. Kombinacija kao što je navedeno u bilo kojem od patentnih zahtjeva 1 do 8, za uporabu u liječenju kognitivnih poremećaja kod pacijenta; naznačena time što je kognitivni poremećaj odabran od Alzheimerove bolesti, šizofrenije, Parkinsonove bolesti, demencije sa Lewyjevim tijelima, vaskularne demencije i frontotemporalne demencije.
10. Spoj 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol za uporabu u kombinaciji sa inhibitorom acetilkolinesteraze i antagonistom receptora NMDA za uporabu u postupku liječenja Alzheimerove bolesti kod pacijenta.
11. Spoj za uporabu kao što je navedeno u patentnom zahtjevu 10, kao dodatno liječenje kod pacijenta koji je na stabilnom liječenju sa inhibitorom acetilkolinesteraze i antagonistom receptora NMDA.
12. Spoj za uporabu kao što je navedeno u patentnom zahtjevu 10 ili patentnom zahtjevu 11, naznačeno time što je inhibitor acetilkolinesteraze odabran od donepezila, rivastigmina i galantamina ili njihove farmaceutski prihvatljive soli.
13. Spoj za uporabu kao što je navedeno u bilo kojem od patentnih zahtjeva 10 do 12, naznačeno time što je antagonist receptora NMDA memantin ili njegova farmaceutski prihvatljiva sol.
14. Spoj za uporabu kao što je navedeno u patentnom zahtjevu 10:
(a) naznačeno time što liječenje sadrži primjenu pacijentu 1 mg do 200 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno, ili
(b) pri čemu liječenje sadrži primjenu pacijentu 1 mg do 10 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno, ili
(c) pri čemu liječenje sadrži primjenu pacijentu 25 mg do 125 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno, ili
(d) pri čemu liječenje sadrži primjenu pacijentu 150 mg do 200 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno, ili
(e) pri čemu liječenje sadrži primjenu pacijentu 25 mg do 75 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno, ili
(f) pri čemu liječenje sadrži primjenu pacijentu 75 mg do 150 mg 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli dnevno; i
(g) pri čemu liječenje sadrži primjenu pacijentu 1 mg do 30 mg donepezila ili njegove farmaceutski prihvatljive soli dnevno; i
(h) pri čemu liječenje sadrži primjenu pacijentu 1 mg do 40 mg memantina ili njegove farmaceutski prihvatljive soli dnevno.
15. Farmaceutski pripravak koji sadrži kombinaciju kao što je navedeno u bilo kojem od patentnih zahtjeva 1 do 8, i farmaceutski prihvatljive ekscipijente ili njihovu kombinaciju.
16. Farmaceutski pripravak kao što je navedeno u patentnom zahtjevu 15, za uporabu u liječenju kognitivnih poremećaja odabranih od Alzheimerove bolesti, šizofrenije, Parkinsonove bolesti, demencije sa Lewyjevim tijelima, vaskularne demencije i frontotemporalne demencije.
17. Farmaceutski pripravak kao što je navedeno u patentnom zahtjevu 15 ili patentnom zahtjevu 16:
(a) naznačen time što je 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol prisutna u količini od 1 mg do 300 mg, ili
(b) pri čemu je 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol prisutna u količini od 35 mg do 200 mg, ili
(c) pri čemu je 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol prisutna u količini od 200 mg do 300 mg, ili
(d) pri čemu je 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol ili njegova farmaceutski prihvatljiva sol prisutna u količini od 75 mg ili 150 mg; i
(e) pri čemu je donepezil ili njegova farmaceutski prihvatljiva sol prisutna u količini od 2 mg do 30 mg; i
(f) pri čemu je memantin ili njegova farmaceutski prihvatljiva sol prisutna u količini od 1 mg do 40 mg.
18. Spoj za uporabu kao što je navedeno u patentnom zahtjevu 10, naznačen time što liječenje sadrži primjenu 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli pacijentu oralnim, nazalnim, lokalnim, dermalnim ili parenteralnim putevima.
19. Spoj za uporabu kao što je navedeno u patentnom zahtjevu 10, naznačen time što liječenje sadrži primjenu 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indola ili njegove farmaceutski prihvatljive soli pacijentu jednom do tri puta dnevno, jednom do tri puta tjedno ili jednom do tri puta mjesečno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| EP16763575.4A EP3458039B1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
| PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201412T1 true HRP20201412T1 (hr) | 2021-02-05 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201412TT HRP20201412T1 (hr) | 2016-05-18 | 2020-09-03 | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (hr) |
| EP (1) | EP3458039B1 (hr) |
| JP (1) | JP6629464B2 (hr) |
| KR (1) | KR102016120B1 (hr) |
| CN (1) | CN109152751A (hr) |
| AU (1) | AU2016407426B2 (hr) |
| BR (1) | BR112018073410A2 (hr) |
| CA (1) | CA3023836C (hr) |
| CY (1) | CY1123644T1 (hr) |
| DK (1) | DK3458039T3 (hr) |
| EA (1) | EA038087B1 (hr) |
| ES (1) | ES2815555T3 (hr) |
| HK (1) | HK1258022A1 (hr) |
| HR (1) | HRP20201412T1 (hr) |
| HU (1) | HUE052077T2 (hr) |
| IL (1) | IL262920B (hr) |
| LT (1) | LT3458039T (hr) |
| MA (1) | MA45002B1 (hr) |
| MD (1) | MD3458039T2 (hr) |
| MX (1) | MX2018014184A (hr) |
| NZ (1) | NZ747797A (hr) |
| PL (1) | PL3458039T3 (hr) |
| PT (1) | PT3458039T (hr) |
| RS (1) | RS60849B1 (hr) |
| SG (1) | SG11201809726UA (hr) |
| SI (1) | SI3458039T1 (hr) |
| WO (1) | WO2017199070A1 (hr) |
| ZA (1) | ZA201807310B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ761037A (en) * | 2017-07-03 | 2022-10-28 | Suven Life Sciences Ltd | New uses of a pure 5-ht6 receptor antagonist |
| MX2022006537A (es) * | 2019-12-02 | 2022-12-13 | Suven Life Sciences Ltd | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
| MX2022006535A (es) * | 2019-12-02 | 2022-09-09 | Suven Life Sciences Ltd | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| NZ572186A (en) * | 2002-11-28 | 2010-02-26 | Suven Life Sciences Ltd | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| DK2521714T3 (en) * | 2010-01-05 | 2015-10-19 | Suven Life Sciences Ltd | Aromatic sulfone compositions useful in the treatment of central nervous disorders |
| HUE036008T2 (hu) | 2013-12-02 | 2018-06-28 | Suven Life Sciences Ltd | Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására |
| CN105085436B (zh) * | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
-
2016
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en unknown
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active IP Right Grant
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 MX MX2018014184A patent/MX2018014184A/es unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2020
- 2020-09-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201412T1 (hr) | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda | |
| HRP20200872T1 (hr) | Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze | |
| HRP20210640T1 (hr) | Kombinacija čistih 5-ht6 antagonista receptora sa nmda antagonistom receptora | |
| JP2009541443A5 (hr) | ||
| HRP20110524T1 (hr) | Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju | |
| HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
| HRP20171977T1 (hr) | Derivati dolastatina 10 i auristatina | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20110697T1 (hr) | Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi | |
| JP2018168191A5 (hr) | ||
| JP2009536176A5 (hr) | ||
| MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
| JP2016501828A5 (hr) | ||
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| RS54670B1 (en) | SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| HRP20201152T1 (hr) | Kondenzirani benzazepin za liječenje mucanja | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| MX2022003177A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol. | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| JP2019516791A5 (hr) |